Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Silence Therapeutics (SLN)
NASDAQ:SLN
Silence Therapeutics (SLN) Stock Price & Analysis
80 Followers
SLN Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$4.55 - $27.72
Previous Close$21.25
Volume141.24K
Average Volume (3M)251.84K
Market Cap
$960.74M
Enterprise Value$951.77M
Total Cash (Recent Filing)£71.14M
Total Debt (Recent Filing)£63.93M
Price to Earnings (P/E)-14.8
Beta1.16
Next Earnings
May 14, 2024EPS Estimate
-$0.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.44
Shares Outstanding36,747,555
10 Day Avg. Volume154,451
30 Day Avg. Volume251,841
Standard Deviation0.24
R-Squared0.09
Alpha0.01
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)95.98
Price to Cash Flow (P/CF)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$57.25Price Target Upside169.41% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Silence Therapeutics News
PremiumCompany Announcements
Silence Therapeutics Announces Upcoming AGM
Bulls Say, Bears Say
Bulls Say
Drug EfficacyZerlasiran achieves over 90% reduction in Lp(a) levels, indicating strong efficacy and potential to lead in the Lp(a) treatment market.
Financial StabilitySilence Therapeutics' current cash position is expected to sustain development efforts well into the future, signaling financial stability.
Market OpportunityWith no approved treatments currently available for lowering Lp(a), Zerlasiran's successful development represents a significant commercial opportunity.
Bears Say
Clinical Development RisksRisks include clinical development risk tied to SLN360, SLN124, and SLN501; competitor risk; novel modality risk; commercialization risk; reimbursement risk; pricing risk; and business development risk.
Drug Safety ConcernsRusfertide's safety profile is characterized by a clinical hold due to safety findings and secondary malignancies in PhII.
Program DiscontinuationThalassemia program discontinued due to variable effects on indicators of iron metabolism.
---
Ownership Overview
0.00%
Insiders
0.05% Mutual Funds
43.09% Other Institutional Investors
56.86% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
SLN FAQ
What was Silence Therapeutics’s price range in the past 12 months?
Silence Therapeutics lowest stock price was $4.54 and its highest was $27.72 in the past 12 months.
What is Silence Therapeutics’s market cap?
Currently, no data Available
When is Silence Therapeutics’s upcoming earnings report date?
Silence Therapeutics’s upcoming earnings report date is May 14, 2024 which is in 19 days.
How were Silence Therapeutics’s earnings last quarter?
Silence Therapeutics released its earnings results on Mar 13, 2024. The company reported -$0.154 earnings per share for the quarter, missing the consensus estimate of -$0.078 by -$0.076.
Is Silence Therapeutics overvalued?
According to Wall Street analysts Silence Therapeutics’s price is currently Undervalued.
Does Silence Therapeutics pay dividends?
Silence Therapeutics does not currently pay dividends.
What is Silence Therapeutics’s EPS estimate?
Silence Therapeutics’s EPS estimate is -$0.12.
How many shares outstanding does Silence Therapeutics have?
Silence Therapeutics has 46,502,274 shares outstanding.
What happened to Silence Therapeutics’s price movement after its last earnings report?
Silence Therapeutics reported an EPS of -$0.154 in its last earnings report, missing expectations of -$0.078. Following the earnings report the stock price went down -1.12%.
Which hedge fund is a major shareholder of Silence Therapeutics?
Among the largest hedge funds holding Silence Therapeutics’s share is Woodline Partners LP. It holds Silence Therapeutics’s shares valued at 856K.
---
Silence Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$57.25 (169.41% Upside)
$57.25 (169.41% Upside)
Blogger Sentiment
Bullish
SLN Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 117.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 4.5%
Last 30 Days ▲ 27.0%
Last 30 Days ▲ 27.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
233.22%
12-Months-Change
Fundamentals
Return on Equity
-222.59%
Trailing 12-Months
Asset Growth
-7.51%
Trailing 12-Months
Company Description
Silence Therapeutics
Silence Therapeutics PLC is one of the leading companies in the ribonucleic acid (RNA) technology field. The United Kingdom-based firm researches and develops therapeutics to combat highly unmet medical needs. Its patented RNA interference platform, known as AtuRNAi is employed in vaccines to correct genetic deficiencies and infectious diseases by silencing or replacing the expression of virtually any gene in the genome, modulating expression up as well as down in a variety of organs and cell types. Its technology is currently in the clinic, in a Phase 2a pancreatic cancer trial and its income consists of license fees, milestone and option payments, grant income and fees from research and development collaborations.
---
SLN Stock 12 Months Forecast
Average Price Target
$57.25
▲(169.41% Upside)
Technical Analysis
Arrowhead Pharmaceuticals
―
Crispr Therapeutics AG
―
Editas Medicine
―
Vertex Pharmaceuticals
―
Best Analysts Covering SLN
1 Year
1 Year Success Rate
5/8 ratings generated profit
1 Year Average Return
+78.84%
assigned a buy rating 5 months ago
Copying Thomas Shrader's trades and holding each position for 1 Year would result in 62.50% of your transactions generating a profit, with an average return of +78.84% per trade.
---